Tang Capital Management’s Standard BioTools LAB Stock Holding History

Tang Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-407,755	Closed	-$530K	–	141
2025 Q3	$530K	Hold	407,755	–	–	0.02%	172
2025 Q2	$489K	Hold	407,755	–	–	0.02%	189
2025 Q1	$440K	Hold	407,755	–	–	0.02%	187
2024 Q4	$714K	Hold	407,755	–	–	0.05%	167
2024 Q3	$787K	Buy	+407,755	New	+$799K	0.06%	129

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Tang Capital Management's LAB Position: Q4 2025 in Review

Tang Capital Management sold out of Standard BioTools (LAB) in Q4 2025, closing a stake of 407,755 shares — an estimated $530K sold.

Tang Capital Management first reported a position in LAB in Q3 2024 and held it in 5 quarters. The position peaked at $787K in Q3 2024. 159 funds tracked by Wall St. Rank hold LAB as of Q4 2025.

Tang Capital Management reported no remaining Standard BioTools position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 407,755 Standard BioTools shares in Q4 2025, an estimated $530K.
Tang Capital Management first reported a position in Standard BioTools in Q3 2024 and held it in 5 quarters.
Tang Capital Management's Standard BioTools position peaked at $787K in Q3 2024.
159 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.